Simcere Receives NMPA Clearance for SIM0348 Clinical Study
China-based Simcere Pharmaceutical Group (HKG: 2096) has announced receiving clearance from the National Medical Products...
China-based Simcere Pharmaceutical Group (HKG: 2096) has announced receiving clearance from the National Medical Products...
China-based chimeric antigen receptor T-cell (CAR-T) specialist Immunotech Biopharm Ltd (HKG: 6978) has announced that...
China-based Acotec Scientific Holdings Ltd (HKG: 6669) has announced receiving market approvals from the National...
The National Medical Products Administration (NMPA) and the General Administration of Customs (GAC) have released...
China-based Yipinhong Pharmacy Co., Ltd (SHA: 300723) has announced that its pipeline candidate AR882, under...
Sino-US siRNA therapy developer Sirnaomics Ltd (HKG: 2257) has announced the interim results of part...
The National Medical Products Administration released a notification extending the validation period of approvals for...
China-based firms CSPC Pharmaceutical Group Ltd (HKG: 1093) and Ascletis Pharma Inc. (HKG: 1672) both...
The National Medical Products Administration (NMPA) website indicates that US-based Viatris Inc.’s (NASDAQ: VTRS) Symfi...
Serve Accurate Faithful Evaluation (SAFE), a contract research organization (CRO) co-founded by the Chinese Academy...
China-based Yifan Pharmaceutical Co., Ltd (SHE: 002019) announced the establishment of a licensing agreement with...
China-based cardiovascular disease solutions provider Lepu Medical Technology (Beijing) Co., Ltd (SHE: 300003) has announced...
China’s National Medical Products Administration (NMPA) has released a notification indicating the initiation of electronic...
The National Medical Products Administration (NMPA) has released a notification regarding the initiation of two...
The Ministry of Finance, General Administration of Customs, State Taxation Administration, and National Medical Products...
The Center for Drug Evaluation (CDE) has released the “NMPA Drug Review Timekeeping Suspension and...
China-based Shanghai Henlius Biotech (HKG: 2696) has announced that the National Medical Products Administration (NMPA)...
China-based CanSino Biologics (SHA: 688185, HKG: 6185) has announced that it has received emergency use...
China-based Luye Pharma Group (HKG: 2186) has announced that it has received market approval from...
China-based Guangzhou Reforgene Medicine Co., Ltd’s in-house developed β-thalassemia gene editing drug RM-001 (HBG gene...